Nature and Science of Sleep (Aug 2023)

Impairment in Functioning and Quality of Life in Patients with Idiopathic Hypersomnia: The Real World Idiopathic Hypersomnia Outcomes Study (ARISE)

  • Stevens J,
  • Schneider LD,
  • Husain AM,
  • Ito D,
  • Fuller DS,
  • Zee PC,
  • Macfadden W

Journal volume & issue
Vol. Volume 15
pp. 593 – 606

Abstract

Read online

Joanne Stevens,1 Logan D Schneider,2 Aatif M Husain,3 Diane Ito,4 Douglas S Fuller,5 Phyllis C Zee,6 Wayne Macfadden1 1Global Medical Affairs, Jazz Pharmaceuticals, Philadelphia, PA, USA; 2Stanford University Sleep Medicine Center, Stanford University School of Medicine, Stanford, CA, USA; 3Duke University Department of Neurology, Duke University Medical Center, Durham, NC, USA; 4Stratevi, Santa Monica, CA, USA; 5Biostatistics, Jazz Pharmaceuticals, Philadelphia, PA, USA; 6Department of Neurology and Center for Circadian and Sleep Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USACorrespondence: Wayne Macfadden, Jazz Pharmaceuticals, 2005 Market Street, Philadelphia, PA, 19103, USA, Tel +1 215-832-3750, Email [email protected]: Idiopathic hypersomnia is a debilitating neurologic sleep disorder characterized by excessive daytime sleepiness, sleep inertia, and prolonged sleep. Its impact on patients’ quality of life and daily functioning has not been fully elucidated. The Real World Idiopathic Hypersomnia Outcomes Study (ARISE) evaluated the daily functioning, relationships, cognition, emotional well-being, and productivity/employment of participants with idiopathic hypersomnia.Patients and Methods: ARISE was a US-based virtual cross-sectional survey comprising multiple patient-reported outcome measures (Functional Outcomes of Sleep Questionnaire, short version [FOSQ-10], Quality of Life in Neurological Disorders [Neuro-QoL] Social Roles and Stigma domains, British Columbia Cognitive Complaints Inventory [BC-CCI], Patient Health Questionnaire [PHQ-9], and the Work Productivity and Activity Impairment Questionnaire: Specific Health Problem [WPAI:SHP]). Participants were adults 21– 65 years of age with idiopathic hypersomnia. Data were analyzed for all participants and for subgroups with/without long sleep time (LST; self-reported sleep ≥ 11 hours in 24 hours).Results: Of 75 participants enrolled, most were female (81.3%) and the mean (SD) age was 34.1 (10.7) years. Participants’ scores on the FOSQ-10 (mean [SD] score: 10.7 [2.8]) and the Neuro-QoL Social Roles (43.4 [4.2]) and Stigma (57.3 [5.9]) domains reflected impairments in daily functioning and quality of life. More than half of participants reported moderate to severe cognitive complaints (BC-CCI; 62.7%) and moderate to severe depressive symptoms (PHQ-9; 66.7%). Scores on the WPAI:SHP showed substantial impairments in absenteeism, presenteeism, overall work productivity, and overall regular daily activity (mean percent [SD]: 12.3 [23.6], 47.6 [22.7], 51.4 [24.7], and 64.0 [21.9], respectively). These considerable impairments were found in participants with and without LST.Conclusion: ARISE participants with idiopathic hypersomnia demonstrated poor quality of life and impaired functioning across multiple symptom domains.Keywords: relationships, social, work productivity, cognitive function, hypersomnolence, long sleep time

Keywords